AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company

COURT OF CHANCERY OF THE SAM GLASSCOCK III VICE CHANCELLOR STATE OF DELAWARE COURT OF CHANCERY COURTHOUSE THE CIRCLE GEORGETOWN, DELAWARE 19947

September 17, 2021

A. Thompson Bayliss, Esquire Kevin R. Shannon, Esquire Joseph A. Sparco, Esquire Christopher N. Kelly, Esquire ABRAMS & BAYLISS LLP Daniel M. Rusk, IV, Esquire Montchanin Rd., Suite 200 POTTER ANDERSON & CORROON LLP Wilmington, DE 19807 1313 N. Market St. Hercules Plaza, 6th Floor Wilmington, DE 19801 RE: AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company Limited, C.A. No. 2020-0953-SG Dear Counsel: I have considered the Defendant’s Motion to Supplement the Trial Record, the Plaintiff’s Motion to Supplement the Trial Record (together, the “Cross- Motions”) and the Plaintiff’s Limited Opposition to Defendant’s Motion to Supplement the Trial Record.

The Cross-Motions are hereby granted, with the exception of Exhibit 1 to the Defendant’s Motion (“Exhibit 1”), which is a gloss on disputed facts that would require supplemental discovery in order for the Plaintiff to address. In any event, Exhibit 1 is not dispositive of my decision.

To the extent the foregoing requires an order to take effect, it is SO ORDERED.

Sincerely, /s/ Sam Glasscock III Vice Chancellor cc: All counsel of record (by File & ServeXpress)